ASPN
Asporin
Also known as: ASPN_HUMAN, FLJ20129, PLAP-1, SLRR1C
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BXN1
- Gene
- ASPN
- Ensembl
- ENSG00000106819
- Chromosome
- 9
- Canonical length
- 380 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Nucleoplasm,Cytosol
- Secretome location
- Secreted to extracellular matrix
OverviewNCBI Gene
This gene encodes a cartilage extracellular protein that is member of the small leucine-rich proteoglycan family. The encoded protein may regulate chondrogenesis by inhibiting transforming growth factor-beta 1-induced gene expression in cartilage. This protein also binds collagen and calcium and may induce collagen mineralization. Polymorphisms in the aspartic acid repeat region of this gene are associated with a susceptibility to osteoarthritis, and also with intervertebral disc disease. Alternative splicing of this gene results in multiple transcript variants.[provided by RefSeq, Jul 2014]
Canonical amino-acid sequenceUniProt
380 residues, UniProt reviewed canonical sequence.
>Q9BXN1|ASPN
1 MKEYVLLLFL ALCSAKPFFS PSHIALKNMM LKDMEDTDDD DDDDDDDDDD DEDNSLFPTR
61 EPRSHFFPFD LFPMCPFGCQ CYSRVVHCSD LGLTSVPTNI PFDTRMLDLQ NNKIKEIKEN
121 DFKGLTSLYG LILNNNKLTK IHPKAFLTTK KLRRLYLSHN QLSEIPLNLP KSLAELRIHE
181 NKVKKIQKDT FKGMNALHVL EMSANPLDNN GIEPGAFEGV TVFHIRIAEA KLTSVPKGLP
241 PTLLELHLDY NKISTVELED FKRYKELQRL GLGNNKITDI ENGSLANIPR VREIHLENNK
301 LKKIPSGLPE LKYLQIIFLH SNSIARVGVN DFCPTVPKMK KSLYSAISLF NNPVKYWEMQ
361 PATFRCVLSR MSVQLGNFGMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ASPN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 129 nTPM
Expression across tissuesHPA
Tissue
- blood vessel: 129 nTPM
- smooth muscle: 103 nTPM
- heart muscle: 89 nTPM
- endometrium: 65 nTPM
- gallbladder: 62 nTPM
- cervix: 38 nTPM
Single-cell type
- hepatic stellate cells: 181 nCPM
- epicardial cells: 127 nCPM
- fibro-adipogenic progenitors: 87 nCPM
- pericytes: 80 nCPM
- fibroblasts: 70 nCPM
- basal keratinocytes: 68 nCPM
Immune cell
- basophil: 1.8 nTPM
- non-classical monocyte: 0.3 nTPM
- eosinophil: 0.2 nTPM
- intermediate monocyte: 0.1 nTPM
- memory B-cell: 0.1 nTPM
- neutrophil: 0.1 nTPM
Brain region
- cerebellum: 4.9 nTPM
- thalamus: 4.1 nTPM
- white matter: 3.9 nTPM
- basal ganglia: 3.7 nTPM
- pons: 3.7 nTPM
- cerebral cortex: 3.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ASPN.
Disease | AllUniProt
Conditions ASPN is implicated in, by any mechanism.
- Osteoarthritis 3 (OS3) MIM:607850
- Intervertebral disc disease (IDD) MIM:603932
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.18
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.75
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- bone mineralization
- negative regulation of tooth mineralization
- negative regulation of transforming growth factor beta receptor signaling pathway
- response to fluoride
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ASPN in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ASPN as an antibody target. Whether an autoantibody or antibody against ASPN could matter depends on whether native ASPN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ASPN is annotated as secreted, so native ASPN circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label ASPN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...